ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9492
0.03%
Brent Oil
84.115
0.69%
Bitcoin
57,793.47
-0.76%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Idera Pharmaceuticals Inc (IDRA)

  7. Idera Pharmaceuticals Inc (IDRA) Noticias

IDRA

Idera Pharmaceuticals (IDRA)

Idera Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IDRA
FechaHoraFuenteTítuloSímboloCompañía
29/06/202315:31Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:IDRAIdera Pharmaceuticals Inc
23/06/202318:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:IDRAIdera Pharmaceuticals Inc
17/05/202308:50Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:IDRAIdera Pharmaceuticals Inc
15/05/202316:08Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:IDRAIdera Pharmaceuticals Inc
13/04/202315:32Edgar (US Regulatory)Annual Report (10-k)NASDAQ:IDRAIdera Pharmaceuticals Inc
10/04/202315:41Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:IDRAIdera Pharmaceuticals Inc
03/04/202305:00Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:IDRAIdera Pharmaceuticals Inc
30/03/202315:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IDRAIdera Pharmaceuticals Inc
28/03/202310:29Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:IDRAIdera Pharmaceuticals Inc
14/02/202316:00Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IDRAIdera Pharmaceuticals Inc
01/02/202315:44Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:IDRAIdera Pharmaceuticals Inc
18/01/202315:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IDRAIdera Pharmaceuticals Inc
17/01/202307:00GlobeNewswire Inc.Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookNASDAQ:IDRAIdera Pharmaceuticals Inc
09/12/202215:50Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:IDRAIdera Pharmaceuticals Inc
14/11/202215:05GlobeNewswire Inc.Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
28/09/202216:01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:IDRAIdera Pharmaceuticals Inc
28/09/202215:09GlobeNewswire Inc.Idera Pharmaceuticals Acquires AceragenNASDAQ:IDRAIdera Pharmaceuticals Inc
09/08/202215:15GlobeNewswire Inc.Idera Pharmaceuticals Reports Second Quarter 2022 Financial ResultsNASDAQ:IDRAIdera Pharmaceuticals Inc
17/05/202207:04GlobeNewswire Inc.Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCNASDAQ:IDRAIdera Pharmaceuticals Inc
05/05/202215:15GlobeNewswire Inc.Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
31/03/202215:26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IDRAIdera Pharmaceuticals Inc
31/03/202215:15GlobeNewswire Inc.Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
14/12/202115:32GlobeNewswire Inc.Idera Pharmaceuticals Announces Tilsotolimod UpdatesNASDAQ:IDRAIdera Pharmaceuticals Inc
08/11/202115:14GlobeNewswire Inc.Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
09/08/202115:15GlobeNewswire Inc.Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
26/05/202105:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:IDRAIdera Pharmaceuticals Inc
19/05/202105:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:IDRAIdera Pharmaceuticals Inc
18/05/202115:15GlobeNewswire Inc.Idera Pharmaceuticals Announces Corporate UpdatesNASDAQ:IDRAIdera Pharmaceuticals Inc
29/04/202115:10GlobeNewswire Inc.Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:IDRAIdera Pharmaceuticals Inc
28/04/202115:55Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IDRAIdera Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IDRA

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
USOTC
BASFY
BASF (QX)
AMEX
SPY
SPDR S&P 500
FX
EURUSD
Euro vs US Dollar
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados